(Reuters) - The success or failure of GlaxoSmithKline's experimental heart drug darapladib remains "an open question" and will hinge on a second pivotal clinical study, the company's chief executive said on Monday.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment